CANCER TREATMENTS

Abstract

Provided are medical uses and methods for targeting cancer stem cells employing ProTide compounds, particularly in the prevention or treatment of cancer. The ProTide may be other than one selected from the group consisting of: NUC-1031; a ProTide derived from cordycepin; and a ProTide derived from 8-chloroadenosine. The medical uses and methods for targeting cancer stem cells are particularly useful in the treatment of relapsed or refractory cancer in human patients. Also provided are methods of selecting patients who will benefit from prevention or treatment of cancer through the medical uses or methods of treatment of the invention.

Claims

1. A method of killing cancer stem cells in a patient with cancer, comprising administering to the patient in need thereof an effective amount of a compound of the formula: ##STR00015## or a pharmaceutically acceptable salt thereof in combination with a chemotherapeutic agent, wherein the cancer is selected from the group consisting of lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer, oral squamous cell carcinoma, urinary bladder cancer, pancreatic cancer, colon cancer, colorectal cancer and gynecological cancer.

2. The method of claim 1, wherein the chemotherapeutic agent is an inhibitor of the VEGF pathway.

3. The method of claim 2, wherein the inhibitor of the VEGF pathway is bevacizumab.

4. The method of claim 1, wherein the chemotherapeutic agent is a mitotic inhibitor.

5. The method of claim 1, wherein the chemotherapeutic agent is a monoclonal antibody.

6. The method of claim 5, wherein the monoclonal antibody is a passive or active immunotherapy.

7. The method of claim 1, wherein the chemotherapeutic agent is a topoisomerase inhibitor.

8. The method of claim 1, wherein the chemotherapeutic agent is a metallic agent.

9. The method of claim 1, wherein the cancer is relapsed or refractory.

10. The method of claim 9, wherein the cancer is relapsed.

11. The method of claim 9, wherein the cancer is refractory.

12. The method according to claim 1, wherein the compound is administered intravenously.

13. The method of claim 1 wherein the cancer is colorectal cancer.

14. The method of claim 1, wherein the cancer is lung cancer.

15. The method of claim 1, wherein the compound and chemotherapeutic agent are administered at the same time.

16. The method of claim 1, wherein the compound and chemotherapeutic agent are administered at the different times.

17. The method of claim 16, wherein the compound is administered prior to the chemotherapeutic agent.

18. The method of claim 15, wherein the compound is administered after the chemotherapeutic agent.

Description

[0161] The invention will now be further described with reference to the following Examples, and the accompanying drawings in which:

[0162] FIG. 1A illustrates the results of investigation of potency of the anti-cancer agent thioinosine, and of ProTide compounds derived from this agent. FIG. 1A compares LD.sub.50 values for thioinosine, CPF 761 and CPF 762. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 1B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 1B provides analysis of leukaemia stem cell targeting capacity of thioinosine and ProTides CPF 761 and CPF 762. All data are the mean (±SD) of three independent experiments.

[0163] FIG. 2A illustrates the results of investigation of potency of the anti-cancer agent clofarabine, and of ProTide compounds derived from this agent. FIG. 2A compares the compares LD.sub.50 values for clofarabine, CPF 448, CPF 720 and CPF 727. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 2B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells.

[0164] FIG. 3A illustrates the results of investigation of potency of the anti-cancer agent clofarabine, and of a ProTide compound (CPF 727) and isomers (A and B) of the ProTide compound CPF 448) derived from this agent, and FIG. 3B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells.

[0165] FIG. 4A illustrates the results of investigation of potency of the anti-cancer agent cladribine, and of ProTide compounds derived from this agent. FIG. 4A compares the compares LD.sub.50 values for cladribine, CPF 791 and CPF 793. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 4B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 4B provides analysis of leukaemia stem cell targeting capacity of cladribine and ProTides CPF 791 and CPF 793. All data are the mean (±SD) of three independent experiments.

[0166] FIG. 5A illustrates the results of investigation of potency of the anti-cancer agent fludarabine, and of ProTide compounds derived from this agent. FIG. 5A compares the compares LD.sub.50 values for fludarabine, CPF 682 and CPF 544. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 5B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 5B provides analysis of leukaemia stem cell targeting capacity of fludarabine, CPF 682 and CPF 544. All data are the mean (±SD) of three independent experiments.

[0167] FIG. 6A illustrates the results of investigation of potency of the anti-cancer agent thioguanosine, and of ProTide compounds derived from this agent. FIG. 6A compares the compares LD.sub.50 values for thioguanosine, and ProTides CPF 775 and CPF 782. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 6B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 6B provides analysis of leukaemia stem cell targeting capacity of thioguanosine, and ProTides CPF 775 and CPF 782. All data are the mean (±SD) of three independent experiments.

[0168] FIG. 7A illustrates the results of investigation of potency of the anti-cancer agent FUDR, and of ProTide compounds derived from this agent. FIG. 7A compares the compares LD.sub.50 values for 5-FU, FUDR and ProTides CPF 373 (mixture) and its purified isomers, CPF 585, CPF 381, and CPF 581. All assays were carried out using KG1a cells and data are presented as mean (±SD) of five independent experiments. FIG. 7B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 7B provides analysis of leukaemia stem cell targeting capacity of 5-FU, FUDR and ProTides CPF 373 (mixture) and its purified isomers, CPF 585, CPF 381, and CPF 581. All data are the mean (±SD) of three independent experiments.

[0169] FIG. 8A illustrates the results of investigation of potency of the anti-cancer agent gemcitabine, and of the comparator ProTide compound NUC-1031 derived from this agent. FIG. 8A compares the compares LD.sub.50 values for gemcitabine, ProTide NUC-1031 and the purified Rp-and Sp-isomers. FIG. 8B illustrates the results of studies investigating the ability of these compounds to target cancer stem cells. FIG. 8B provides analysis of leukaemia stem cell targeting capacity of gemcitabine and NUC-1031 ProTides. All data are the mean (±SD) of three independent experiments.

EXAMPLES AND COMPARATIVE EXAMPLES

1 Preferential Targeting of Cancer Stem Cells by ProTide Compounds

[0170] The following study illustrates the ability of ProTide compounds, as defined herein, to preferentially target CSCs in vitro, and thereby reduce the proportion of CSCs present in populations of cancer cells. The cancer stem cell targeting ability of ProTide compounds encompassed by the present invention is compared with that of the comparator ProTide compound, NUC-1031.

1.1 Comparison of LD.sub.50 Values for ProTide Compounds and the Parent Compounds from which they are Derived in Primary Acute Myeloid Leukaemia Blasts

[0171] ProTide compounds, as defined herein, and the comparator ProTide compound NUC-1031 were assayed for their cytotoxic effects on primary cultures of acute myeloid leukaemia (AML) blasts. LD.sub.50 values (the concentration required to kill 50% of the tumour cells in culture) were calculated in respect of the ProTide compounds of the invention, and the parent compounds from which they are derived. As can be seen (set out below) certain of the ProTide compounds exhibited greater potency than the parent compounds from which they were derived. The LD.sub.50 values of the ProTide compounds as defined herein (and their parent compounds) were compared with the comparator ProTide NUC-1031 and its parent compound gemcitabine.

TABLE-US-00002 Parent compound ProTide compound CPF 581 0.027 μM FUDR 1.18 μM CPF 381 0.039 μM FUDR 1.18 μM CPF 373 (mix) 0.053 μM FUDR 1.18 μM CPF 373 (Iso A) 0.052 μM FUDR 1.18 μM CPF 373 (Iso B) 0.055 μM FUDR 1.18 μM CPF 585 0.79 μM FUDR 1.18 μM CPF 782 0.82 μM Thioguanosine 1 μM Comparator ProTide compound NUC-1031 0.28 μM Gemcitabine 1.4 μM

In Vitro Cytotoxicity Assay in Primary Acute Myeloid Leukaemia Cells

[0172] Bone marrow samples were collected in ethylenediaminetetraacetic acid (EDTA) from newly diagnosed, previously untreated, acute myeloid leukaemia (AML) patients. AML blasts were enriched by density gradient centrifugation using Histopaque (Sigma, Poole, UK) and were subsequently maintained in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% foetal bovine serum (FBS). Cells were treated with ProTide compounds (either as encompassed by the present invention, or the comparator ProTide NUC-1031) or with the ProTides' parent compounds at a range of experimental concentrations, and incubated for 48 h. All cultures were maintained at 37° C. in a 5% CO.sub.2 humidified atmosphere.

Measurement of In Vitro Apoptosis in Primary AML Cells

[0173] Cells were harvested and labelled with CD34-fluorescein isothiocyanate (FITC) (BD Biosciences, Buckingham, UK) and then resuspended in 200 μl of binding buffer containing 4 μl of annexin V labelled with allophycocyanin (APC) (eBioscience Ltd, Hatfield, UK). Apoptosis was quantified in the CD34.sup.+ AML cells using an Accuri C6 flow cytometer (Becton Dickinson, CA, USA). At least 10,000 events were acquired and data were subsequently analysed using FlowJo software (Tree Star Inc., Ashland, OR, USA). All LD.sub.50 values (concentration of drug required to kill 50% of cells) were derived from the dose-response curves.

[0174] Identification and Quantification of CD34.sup.+/CD123.sup.+ Sub-Populations in Primary AML Cells Putative leukaemic stem cells were identified by dual expression of CD34 and CD123. The relative sensitivity of these cells to the effects of ProTides and their parent compounds were assessed as a function of the percentage of these cells that remained viable following exposure to molar equivalents of each agent.

[0175] The results of this study allowed the calculation of mean LD.sub.50 value obtained in respect of both ProTide compounds and the parent anti-cancer agents from which they are derived. Increased potency of ProTide derivatives was indicated LD.sub.50 values lower than those of their parent compound, and the results obtained in this study are discussed further below.

[0176] The ability of ProTide compounds and their parent anti-cancer agents to deplete CSCs in the AML blast cultures at a range of experimental concentrations was also investigated, and the results reported below. The ability of a ProTide or parent compound to target stem cells is demonstrated by a reduction in the proportion of cancer stem cells present in a population of treated cells.

1.2 Preferential Targeting of CSCs by NUC-1031

[0177] The respective abilities of NUC-1031 and gemcitabine to target CSCs were investigated in the AML cell line KG1a. The KG1a cell line was chosen in particular for this study because CSCs within the population exhibit a Lin.sup.−/CD34.sup.+/CD38.sup.−/CD123.sup.+ immunophenotype that allows them to readily be distinguished from non-stem cancer cells (also termed “bulk” cancer cells) within the population.

1.3 KG1a Cell Culture Conditions

[0178] The acute myeloid leukaemia (AML) KG1a cell line was maintained in RPMI medium (Invitrogen, Paisley, UK) supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin and 20% fetal calf serum. Cells were subsequently aliquoted (10.sup.5 cells/100p) into 96-well plates and were incubated at 37° C. in a humidified 5% carbon dioxide atmosphere for 72 h in the presence of NUC-1031 or gemcitabine at concentrations that were experimentally determined for each compound. In addition, control cultures were carried out to which no drug was added. Cells were subsequently harvested by centrifugation and were analysed by flow cytometry using the Annexin V assay.

1.4 Measurement of In Vitro Apoptosis

[0179] Cultured cells were harvested by centrifugation and then resuspended in 195 μl of calcium-rich buffer. Subsequently, 5 μl of Annexin V (Caltag Medsystems, Botolph Claydon, UK) was added to the cell suspension and cells were incubated in the dark for 10 mins prior to washing. Cells were finally resuspended in 190 μl of calcium-rich buffer together with 10 μl of propidium iodide. Apoptosis was assessed by dual-colour immunofluorescent flow cytometry as described previously. Subsequently LD.sub.50 values (the dose required to kill 50% of the cells in a culture) were calculated for each nucleoside analogue and ProTide.

1.5 Immunophenotypic Identification of the Leukaemic Stem Cell Compartment

[0180] KG1a cells were cultured for 72 hours in the presence of a wide range of concentrations of each nucleoside analogue and their respective ProTides. Cells were then harvested and labelled with a cocktail of anti-lineage antibodies (PE-cy7), anti-CD34 (FITC), anti-CD38 (PE) and anti-CD123 (PERCP cy5). The sub-population expressing a leukaemic stem cell (LSC) phenotype were subsequently identified and were expressed as a percentage of all viable cells left in the culture. The percentages of stem cells remaining were then plotted on a dose-response graph and the proportion of cancer stem cells was compared across the various concentrations of ProTides and their respective parent compounds, in order to determine if they preferentially target cancer stem cells.

1.6 Statistical Analysis

[0181] The data obtained in these experiments were evaluated using one way ANOVA. All data was confirmed as Gaussian or a Gaussian approximation using the omnibus K2 test. LD.sub.50 values were calculated from the non-linear regression and line of best-fit analysis of the sigmoidal dose-response curves. All statistical analyses were performed using Graphpad Prism 6.0 software (Graphpad Software Inc., San Diego, Calif.).

1.7 Thioinosine and ProTide Derivatives of Thioinosine

[0182] ProTide derivatives of Thioinosine exhibited reduced potency as compared to the parent compound (FIG. 1A).

[0183] In KG1 a cells, treatment with Thioinosine, CPF-761 or CPF-762 resulted in a reduction of the proportion of cancer stem cells as compared to non-stem cancer cells (FIG. 1), suggesting that Thioinosine, CPF-761 and CPF-762 preferentially target cancer stem cells.

[0184] Additionally, CPF-761 and CPF-762 showed greater selectivity against cancer stem cells than Thioinosine. Of the three compounds, CPF-761 appeared to be the most selective against cancer stem cells, and the increase in selectivity was statistically significant as compared to the parent compound.

1.8 Clofarabine and ProTide Derivatives of Clofarabine

[0185] CPF-727, a ProTide derivative of clofarabine exhibited potency that did not significantly differ from that of the parent compound, whereas ProTides CPF-448 and CPF-720 both exhibited reduced potency as compared to the parent compound (FIG. 2A). Further investigation of the properties of Isomers A and B of CPF-448 indicated that both of these were significantly less potent than the parent compound, but that Isomer A was significantly more potent than Isomer B.

[0186] In KG1a cells, treatment with Clofarabine, CPF-448, CPF-720 or CPF-727 showed a reduction in the proportion of cancer stem cells as compared to non-stem cancer cells (FIG. 2A). This suggests that Clofarabine, CPF-448, CPF-720 and CPF-727 also preferentially target cancer stem cells. This selective effect was observed even at a very low concentration of approximately 6×10.sup.−8 M. It should also be noted that CPF-448 showed greater selectivity against cancer stem cells than Clofarabine itself.

[0187] When the ability of the different isomers of CPF-448 to selectively target cancer stem cells was investigated, Isomer A proved to be more selective than Isomer B, and only Isomer A showed a statistically significant increase in selectivity. This increase in selectivity was noted both in comparison to the parent compound, and ProTide compound CPF-727 (FIG. 3B).

1.9 Cladribine and ProTide Derivatives of Cladribine

[0188] ProTide derivatives of cladribine exhibited reduced potency as compared to the parent compound (FIG. 4A).

[0189] In KG1a cells, treatment with Cladribine, CPF-791 or CPF-793, resulted in a reduction in the proportion of cancer stem cells as compared to non-stem cancer cells (FIG. 4B), suggesting that these three compounds also preferentially target cancer stem cells. The reduction in proportion of cancer stem cells was particularly striking in cells treated with CPF-793. The selectivity of this compound was observed even at a very low concentration (approximately 6×10.sup.−8 M).

[0190] Additionally, both ProTide derivatives (CPF-791 and CPF-793) showed a greater selectivity against cancer stem cells than the parent compound—Cladribine. This increase in selectivity was statistically significant in respect of ProTide CPF-793.

1.10 Fludarabine and ProTide Derivatives of Fludarabine

[0191] ProTide derivatives of fludarabine exhibited reduced potency as compared to the parent compound (FIG. 5A).

[0192] In KG1a cells, treatment with Fludarabine, CPF-544 or CPF-682 resulted in a significant decrease in the proportion of cancer stem cells as compared to non-stem cancer cells (FIG. 5B). This shows that Fludarabine, CPF-544 or CPF-682 preferentially target cancer stem cells. The selectivity of the ProTide derivatives (CPF-544 and CPF-682) against cancer stem cells was found to be comparable to that of Fludarabine.

1.11 Thioguanosine and ProTide Derivatives of Thioguanosine

[0193] ProTide derivatives of thioguanosine exhibited reduced potency as compared to the parent compound (FIG. 6A).

[0194] In KG1a cells, treatment with Thioguanosine, CPF-782 or CPF-775 showed a strong reduction in the proportion of cancer stem cells as compared to non-stem cancer cells (FIG. 6B). This indicates that all three compounds preferentially target cancer stem cells. Of these compounds, CPF-782 was the most selective, but both CPF-782 and CPF-775 exhibited statistically significant increases in selectivity at certain concentrations.

1.12 FUDR and ProTide Derivatives of FUDR

[0195] When the in vitro potency of FUDR and ProTides CPF-585, CPF-373 (Iso A), CPF-373 (Iso B), CPF-381 or CPF-581 (all derived from FUDR) was studied, it was found that all of the ProTide derivatives other than CPF-585 have significantly greater potency than FUDR (FIG. 7A). For example, the LD.sub.50 value of CPF-581 was found to be 0.027 μM, compared to the LD.sub.50 value of FUDR, equal to 1.18 μM, indicating that CPF-581 is over 50 times more potent than FUDR.

[0196] In KG1a cells, treatment with FUDR, CPF-585, CPF-373 (Iso A), CPF-373 (Iso B), CPF-381 or CPF-581 showed a reduction in the proportion of cancer stem cells as compared to non-stem cancer cells, indicating that the treatments preferentially target cancer stem cells (FIG. 7B). The reduction in cancer stem cells was especially significant in cells treated with CPF-373 (Iso A), CPF-373 (Iso B), CPF-381 or CPF-581, where the proportion of cancer stem cell numbers was reduced even in cells treated at a very low concentration of approximately 8×10.sup.−8 M. It should also be noted that all of the above mentioned ProTide derivatives of FUDR, showed a greater selectivity against cancer stem cells than FUDR, with the increase in selectivity being statistically significant in the case of the isoforms of CPF-373.

1.13 Comparative Example: NUC-1031 Preferentially Targets Cancer Stem Cells

[0197] In KG1a cells, NUC-1031 (and its purified isomers) showed increased in vitro potency when compared to Gemcitabine (FIG. 8A). However, there was no significant difference in potency between the unseparated mixture and the purified isomers of NUC-1031.

[0198] NUC-1031 showed preferential targeting of CSCs when compared with Gemcitabine. This was consistently observed at sub-micromolar concentrations of ProTide (FIG. 8B). Again, the two purified isomers of NUC-1031 showed no significant difference in their ability to target CSCs in our experimental system.

[0199] It can be seen that the biological activity of NUC-1031 in vitro closely resembles that observed in respect of a number of the other ProTide compounds referred to above. Accordingly, the inventors have sound reasons to believe that these ProTide compounds will also share the clinical efficacy of NUC-1031, which is discussed further in the following comparative Example.

2 Comparative Clinical Example: NUC-1031 is Able to Treat Relapsed or Refractory Cancers in Human Patients

[0200] The following data were generated in clinical studies of NUC-1031 in human patients with advance progressive cancers that are refractory to, or have relapsed on, all conventional therapies that have been used to date. The results clearly illustrate the ability of NUC-1031 to successfully treat refractory cancers.

[0201] Although the primary objectives of the dose escalation part of the study were to determine the Recommended Phase II Dose (RP2D) and safety profile, secondary objectives included determining the PK profile, however effective treatment of patients with a range of refractory cancers has also been observed as part of this study.

[0202] A total of 68 patients have been entered into this dose escalation study, of which 49 were evaluable for clinical response in that they have received at least 2 Cycles of NUC-1031 and were therefore eligible for a RECIST 1.1 assessment.

TABLE-US-00003 TABLE 1 Best Overall Response in the ProGem1 Study Patients n = 68 Best Overall Response (to date) Evaluable n = 49 Partial Responses  5 (10%) Stable Disease 33 (67%) Progressive Disease 11 (22%) Non Evaluable n = 19
NUC-1031 was administered as a 5 to 30 minute intravenous slow bolus injection.
Schedule A: NUC-1031 was administered on days 1, 8, 15 of a 4 weekly Cycle.
Schedule B: NUC-1031 was administered on days 1, 5, 8, 12, 15, 19, of a 4 weekly Cycle.
Evaluable Patients [n=49]

[0203] Evaluable patients were patients that received ≥2 Cycles of NUC-1031 and were therefore eligible for a RECIST 1.1 assessment at the end of Cycle 2. Where the disease response duration, measured in months, is followed by a “+” this indicates ongoing disease control as of the latest cut-off date.

Patient 004 Breast Cancer: Stable Disease

[0204] Female (67 years)

[0205] Diagnosed with Grade 2 invasive ductal carcinoma of the breast (ER+ve, HER2−ve) in 2002. As first line treatment she was given surgery and received adjuvant epirubicin+docetaxel, radiotherapy and maintenance hormone therapy with tamoxifen, then anastrozole until 2010. In 2010, patient was diagnosed with metastatic disease in the bone and was treated with palliative radiotherapy and commenced on ibondronate and fulvestrant as second line treatment.

[0206] Disease progression was noted in 2012 and she was given third line chemotherapy with capecitabine and navelbine for 4 months, but while on treatment her disease progressed, with new liver and lung metastases. The patient was commenced on a PI3K inhibitor (Phase 1 study) in September 2012 and received 2 Cycles (2 months), but disease progressed, with increase in the size of liver metastases, while on treatment.

[0207] Commenced NUC-1031 on 3 Dec. 2012 on 500 mg/m.sup.2 weekly. Completed 6 Cycles and tolerated treatment well. Patient had Stable Disease at end of study and requested compassionate continuation of a 7.sup.th Cycle of NUC-1031, then elected for a ‘drug holiday’ after Cycle 7. Remained stable for further 5 months with no further treatment before disease progression.

Stable Disease to RECIST (12 months).

Patient 005 Ovarian Cancer: Stable Disease

[0208] Female (58 years)

[0209] Diagnosed with Stage 3c (Grade 3) bilateral serous ovarian cancer in 2009. On the 23 Jun. 2009 the patient had a total abdominal hysterectomy and salpingo-oopherectomy performed, but unresectable omental deposits were left in situ.

[0210] As first line chemotherapy, in October 2009 the patient received 6 Cycles of carboplatin+paclitaxel, but developed an allergic reaction to carboplatin at final treatment Cycle.

[0211] First relapse was 8 months later and in December 2010 patient commenced on 6 Cycles of Caelyx plus VEGFR-2 inhibitor (Phase II clinical study), remaining on VEGFR-2 monotherapy as maintenance. Second relapse was 9 months later, with a rise in CA125 and CT evidence of a left sided pelvic mass measuring 3.2 cm. Commenced on third line chemotherapy and received 6 Cycles of weekly paclitaxel and there was an initial moderate response with a fall in CA125 and some reduction in tumour volume. Disease progression was confirmed 5 months later with rising CA125 levels and increased tumour size. Patient received the last dose of paclitaxel in March 2012.

[0212] Commenced NUC-1031 on 7 Jan. 2013 on 500 mg/m.sup.2 weekly. Completed 6 Cycles as per Study protocol, with Stable Disease, and then a further 6 months of NUC-1031, resulting in 12 months of treatment. Patient tolerated treatment well. CA125 levels dropped from 208 at start of study to 140 at the end of Cycle 6. Patient elected to stop therapy after 12 months, and relapsed 3 months after stopping treatment.

Stable Disease to RECIST (15 months).

Patient 006 Cholangiocarcinoma: Stable Disease

[0213] Male (43 years)

[0214] Diagnosed with a primary cholangiocarcinoma in 2009. A Whipple procedure was performed and the patient was given 6 cycles of adjuvant gemcitabine. On disease recurrence in February 2012, the patient was commenced on CapeOx until July 2012. Later that year a CT scan showed bone metastases and these were treated with a course of radiotherapy to the lower back.

[0215] Commenced NUC-1031 on 31 Jan. 2013 on 375 mg/m.sup.2 twice weekly, and completed 2 Cycles. Changed to schedule A at 500 mg/m.sup.2 and received 1 further dose. Reduction in CA19.9 from 125,002 to 59,285 after only two doses of NUC-1031. CT scan revealed a reduction in metastatic lung lesion and lymph node from baseline.

Stable Disease to RECIST (3 months).

Patient 007 Colorectal Cancer: Stable Disease

[0216] Male (73 years)

[0217] Diagnosed with colorectal cancer in 2008. Following 6 Cycles of FOLFOX had the primary tumour removed in April 2009. Further surgery in August 2009 when a right hepatectomy and ileostomy were performed. In July 2010 was included in the PICCOLO trial (panitumumab+irinotecan). Six months later received radiofrequency ablation (RFA) plus biliary stenting for additional complications. In December 2011 he received 7 Cycles of cetuximab+irinotecan+5-FU, but with subsequent disease progression.

[0218] Commenced NUC-1031 on 11 Feb. 2013 on 375 mg/m.sup.2 twice weekly, and completed 0.5 of a Cycle.

[0219] Following treatment delays, and at the patient's request for convenience, he was changed to a weekly schedule at 500 mg/m.sup.2 and completed 2 Cycles. Over the treatment period he developed thrombocytopaenia (G3) (possible linked to splenomegaly seen at baseline). An ultrasound scan on 25 Feb. 2013 showed compression of portal vein, with possible thrombosis, as a result of the splenomegaly. Reduction in CEA from 361 to 286 and CA19.9 from 3,151 to 2,957.

Stable Disease to RECIST (3 months).

Patient 008 Cancer of Unknown Primary: Stable Disease

[0220] Female (37 years)

[0221] Diagnosed with a retroperitoneal mass and metastatic disease of unknown primary in 2012. Rapid tumour progression following 4 Cycles of gemcitabine+cisplatin from August 2012.

[0222] Commenced NUC-1031 on 12 Feb. 2013 on 375 mg/m.sup.2 twice weekly, and completed 2 Cycles. During Cycle 1 patient had symptomatic relief on treatment and a general improvement in mood and wellbeing. Developed transient (G3) transaminitis (ALT and AST). Lymphoedema, which was present at baseline, was progressing during Cycle 2.

Also developed a pleural effusion (G3) that was assessed as unlikely to be related to study drug.
Stable Disease to RECIST (3 months).

Patient 010 Endometrial Cancer: Stable Disease

[0223] Female (60 years)

[0224] Diagnosed with endometrial cancer (stage IV, grade 3) in 2012. In February 2012 the patient received radiotherapy to a pelvic mass and 6 Cycles of carboplatin+paclitaxel. On disease progression in November 2012 received 3 Cycles of paclitaxel, and then rapidly progressed through a Cycle of Megace in January 2013.

[0225] Commenced NUC-1031 on 19 Mar. 2013 on 750 mg/m.sup.2 weekly, and completed 1 Cycle. Developed neutropenia (G3) during Cycle 1, which resolved after a few days, following intervention with GCSF. Dose reduced to 500 mg/m.sup.2 for Cycle 2 and completed 5 Cycles at this dose. Patient had transient Grade 3 anaemia. Reduction in CA125 from 727 to 488. Patient had Stable Disease on study and this was maintained for a further 3 months after stopping NUC-1031.

Stable Disease to RECIST (9 months).

Patient 011 Uterine Carcinosarcoma: Stable Disease

[0226] Female (67 years)

[0227] Diagnosed with uterine carcinosarcoma (recurrent MMMT of the uterus) and liver, lung and para-aortic nodal metastases. Surgery was performed in June 2011 with a radical hysterectomy and bilateral salpingo-oophorectomy. From June 2011 to November 2012 the patient received adjuvant cisplatin and doxorubicin-6 cycles completed (good response to treatment with almost complete remission).

[0228] June 2012 underwent further surgery with an anterior exenteration, dissection of rectum and repair and formation of ileal conduit with end-to-end anastomosis. Further surgery in June 2012 when she underwent a laparotomy with implantation of a ureter in to her ileal conduit and a Hartman's procedure for a rectal fistula. March 2013 completed 6 Cycles of weekly paclitaxel but with tumour progression through this course of treatment.

[0229] Commenced NUC-1031 on 15 Apr. 2013 on 375 mg/m.sup.2 twice weekly, and completed 2.6 Cycles. Patient had stable disease to RECIST with a reduction in tumour volume of 26%. During treatment had transient neutropaenia (G3) and a low haemoglobin (G2). At patient's request, changed to weekly schedule at 625 mg/m.sup.2 for Cycle 4, and completed 1 further Cycle. The end of Cycle 4 (end Month 4) CT scan in August 2013 showed progressive disease. Three new lesions appeared: 2 in the lung, and 1 retro cava lymph node. The original lesion in the liver had continued to decrease in size and the other target lesion in the lung had remained stable. The patient was withdrawn from the study.

Stable Disease to RECIST (4 months).

Patient 012 Cholangiocarcinoma: Stable Disease

[0230] Female (48 years)

[0231] Diagnosed with Stage IV, Grade 3 cholangiocarcinoma in 2013 following investigation for right-sided abdominal pain. CT scan showed liver, lung and peritoneal metastases. From January-Aprril 2013 the patient received 3 Cycles of cisplatin+gemcitabine, with rapid disease progression.

[0232] Commenced NUC-1031 on 16 May 2013 on 375 mg/m.sup.2 twice weekly, and completed 3 Cycles. At patient's request changed to weekly schedule at 625 mg/m.sup.2 for Cycle 4, completed 3 further Cycles and tolerated treatment well. Patient had Stable Disease at end of study and had a further two Cycles, with a total of 8 Cycles.

Stable Disease to RECIST (8 months).

Patient 013 Cervical Cancer: Partial Response

[0233] Female (51 years)

[0234] Diagnosed with inoperable, poorly differentiated squamous cell cervical cancer (Stage 2b, G2/3) in September 2011. She was treated with cisplatin (4 Cycles) plus radiotherapy and was said by the referring clinician to have a “good response”.

[0235] In July 2012 the patient developed disease progression and, between July 2012 and November 2012, was given 6 doses of carboplatin+paclitaxel plus Cediranib (CIRCCA trail) and achieved stable disease. In April 2013 MRI scan showed disease progression with increased iliac lymph node involvement.

[0236] Commenced on NUC-1031 on 28 May 2013 on 750 mg/m.sup.2 weekly, and completed 2 Cycles. Dose reduced to 625 mg/m.sup.2 and completed 4 further Cycles. Had lower pelvic pain prior to study but had relief of this pain on treatment, with significant reduction of opioid usage. The patient had problems with recurrent urinary tract infections both before starting NUC-1031 and during treatment because of bilateral metal ureteric stents.

[0237] Patient had a Partial Response at completion of the ProGem1 study and then completed a further 3 Cycles on a reduced dose of 500 mg/m.sup.2 weekly, with a total of 9 Cycles of NUC-1031. Patient's tumour has shrunk to the extent that she was being re-evaluated for further debulking surgery.

Partial Response to RECIST (9 months, PFS 11 months).

Patient 014 Mesothelioma: Progressive Disease

[0238] Female (51 years)

[0239] Patient diagnosed with a recurrent epitheliod mesothelioma in the right hemi-thorax in 2012. Received 4 Cycles of permetrexed+carboplatin. On progression in December 2012 entered a clinical study to receive dasatinib but was unresponsive and had disease progression.

[0240] Commenced on NUC-1031 on 20 Jun. 2013 on 750 mg/m.sup.2 weekly, and completed 1 Cycle. Dose reduced to 625 mg/m.sup.2 and completed 1 further Cycle. Withdrawn from study. Progressive Disease.

Patient 015 Cancer (Unknown Primary): Partial Response

[0241] Male (54 years)

[0242] Diagnosed with cancer of unknown primary in September 2012, having been investigated for symptoms of abdominal pain.

[0243] He was noted at that time to have liver and lung metastases. A liver biopsy showed a poorly differentiated carcinoma with focal glandular differentiation. Received 8 Cycles of epirubicin+cisplatin+capecitabine from October 2012 until April 2013 within the “CUP” clinical study but developed Progressive Disease with oedema, pleural effusion and ascites, with a 20 kg weight gain. Patient experienced severe nausea and vomiting and fatigue on this regimen.

[0244] Commenced on NUC-1031 on 20 Jun. 2013 on 750 mg/m.sup.2 weekly, and received 2 doses. Dose reduced to 625 mg/m.sup.2 to complete Cycle 1 and received 5 further Cycles at the lower dose. On study entry patient had marked lower limb oedema and abdominal ascites (approximately 20 Kg). Following Cycle 1 it was reported that the oedema and ascites had gone and the patient was feeling much better. During Cycle 1 Day 8 developed thrombocytopenia (G3), lymphopenia (G3) and neutropenia (G2) which caused a two week treatment delay. End of Cycle 2 scan showed a reduction in all target lesions with a RECIST assessment of Stable Disease. End of Cycle 4 scan showed further reduction in all target lesions, with a RECIST assessment of a Partial Response, which was sustained until end of study. Requested compassionate continuation and completed 3 further Cycles at this dose. Was beginning to show a consistent drop in blood counts following Day 8 of each Cycle.

[0245] From Cycle 10 dose reduced further to 500 mg/m.sup.2 with the desired effect and completed a further 10 Cycles (19 in total).

[0246] Most recent CT scan on 9 Jan. 2015 showed sustained Partial Response (approximately 58% reduction in tumour size) and the target mesenteric node no longer visible. Had fluid build up in both legs during Cycle 10 but responded well to spironolactone and completely resolved. Replaced Hickman line on 12 Dec. 2014 following 19 months in situ, with no adverse effect. Patient remains clinically very well. Following discussions with CI Patient is happy to have a treatment break and will be referred back to oncologist to discuss options.

Partial Response to RECIST (20+ months; PFS 24+ months) ongoing.

Patient 017 Lung Cancer: Partial Response

[0247] Female (60 years)

[0248] Diagnosed with lung adenocarcinoma, with lung, liver and adrenal metastases in September 2011. Also had disease in mediastinal, intra abdominal and cervical lymph nodes. The patient had a pleurodesis performed in December 2011 followed by 3 Cycles of cisplatin+pemetrexed which she completed in March 2012 and achieved a partial response. From March-September 2012 she received a total of 6 Cycles of docetaxel, with a partial response. In April 2013 she had disease progression and was re-challenged with docetaxel, but progressed through 2 Cycles of docetaxel.

[0249] Commenced on NUC-1031 in July 2013 on 750 mg/m.sup.2 weekly and received 1 dose. Dose reduced to 625 mg/m.sup.2 and she received 2 doses to complete Cycle 1 and has completed 5 further Cycles. Had 4 weeks of treatment delays due to lung infections and low platelets. Significant response in diseased lymph nodes, particularly in the neck.

Target lesions continued to shrink which was evident on post Cycle 2 and Cycle 4 CT scans. At this stage, RECIST assessment classified the response as Stable Disease.

[0250] At the end of Cycle 6 a CT scan showed further reduction and the RECIST assessment was changed to a Partial Response in all target lesions at end of study. Requested continuation on a compassionate use basis and completed 3 further Cycles. Patient tolerated NUC-1031 well, with improvement in hoarse voice and dysphagia. End of Cycle 9 scan on 17 Apr. 2014 showed Progressive Disease with a growth on target lesions and new hepatic lesions. Withdrawn from study.

Partial Response to RECIST (3 months; PFS 10 months).

Patient 018 Lung Cancer: Stable Disease

[0251] Female (65 years)

[0252] Diagnosed with squamous cell lung cancer May 2011. Receivedgemcitabine+cisplatin, 6 Cycles from June to October 2011 within the SQUIRE trial. Disease relapse in April 2012 and she received single fraction palliative radiotherapy to right hilum and docetaxel 6 Cycles from May until September 2012.

[0253] Progressive disease October 2012. Commenced erlotinib December 2012 for 3 months but in March 2013 was found to have progressive disease in the right hilum.

[0254] Commenced on NUC-1031 on 25 Jul. 2013 on 625 mg/m.sup.2 weekly, and completed 4 Cycles. Stable disease to RECIST (4 months). Patient withdrawn from study due to symptomatic deterioration caused by vena caval obstruction. Received low dose radiotherapy in an attempt to resolve the obstruction and recommenced NUC-1031 on the compassionate access programme. Following one further dose of NUC-1031 it was agreed to withdraw patient from the compassionate access programme. The bulk of the patient's disease was stable on withdrawal.

Stable Disease to RECIST (4 months).

Patient 021 Fallopian Tube Cancer: Partial Response

[0255] Female (61 years)

[0256] Diagnosed with recurrent Stage 2a, Grade 2 endometrioid adenocarcinoma of the ovary in 2008. She received 6 Cycles of carboplatin+paclitaxel, completed October 2008. In June 2011 she relapsed and was noted to have pleural, subcapsular liver, omental and mesenteric tumour nodules and was recruited into the ICON6 study, receiving 6 Cycles of carboplatin plus paclitaxel+/−cediranib. She achieved a partial response to therapy. Remained on maintenance cediranib until March 2012 when treatment was discontinued due to rising CA125 and progressive peritoneal disease.

[0257] From March to July 2012 she received 6 Cycles of weekly paclitaxel with good radiological response initially of the peritoneal disease. In February 2013 she was found to have a new effusion and an increase in the peritoneal disease. She commenced carboplatin+paclitaxel and daily AKT inhibitor on the AKTRES study but with disease progression (new pelvic mass) in May 2013 after 3 Cycles.

[0258] Commenced on NUC-1031 on 28 Aug. 2013 on 625 mg/m.sup.2 weekly, and completed 6 Cycles. Noticed a significant reduction in abdominal ascites; required drainage every two weeks prior to coming on study and has not required further drainage since commencing NUC-1031. Patient tolerated NUC-1031 well. Stable disease to RECIST at end of study. Requested continuation on compassionate use basis and completed one further Cycle. End of Cycle 7 CT scan on the 26 Feb. 2014 showed a further reduction in tumour volume which confirmed Partial Response to RECIST. Significant CA125 Response: 91% reduction from baseline (372) to end of Cycle 6 (35).

[0259] Best overall response to date is Partial Response (3 months) according to RECIST or Partial Response (9 months) according to GCIG criteria.

Partial Response.

Patient 024 Cancer of Unknown Primary: Progressive Disease

[0260] Female (51 years)

[0261] Diagnosed with cancer of unknown primary in April 2012. Received CAPOX, 8 Cycles from April to October 2012. Received irinotecan in October 2012 with addition of bevacizumab in November 2012, but without response.

[0262] Commenced on NUC-1031 on 26 Sep. 2013 on 675 mg/m.sup.2 weekly, and completed 2 Cycles. End of Cycle 2 CT scan showed progressive disease.

Progressive Disease.

Patient 025 Mesothelioma: Stable Disease

[0263] Male (54 years)

[0264] Diagnosed with T4 N3 M0 epithelioid mesothelioma of the right lung in March 2013. Received 4 Cycles of pemetrexed+cisplatin from May to August 2013.

[0265] Commenced on NUC-1031 on 23 Oct. 2013 on 725 mg/m.sup.2 weekly, and completed 4 Cycles. End of C4 CT Scan showed Progressive Disease. Withdrawn from study.

Stable Disease to RECIST (4 months).

Patient 026 Colorectal Cancer: Stable Disease

[0266] Female (63 years)

[0267] Diagnosed with colorectal cancer, T4 N2, with lung and bladder metastases in February 2007. Received adjuvant FOLFOX, 12 Cycles, November 2007. Developed pelvic recurrent disease and received capecitabine 2009.

[0268] On relapse in 2012 received FOLFIRI in September 2012 and capecitabine+irinotecan until January 2013. In July 2013 CT showed Progressive Disease, presacral tumour recurrence causing destruction of sacrum, and a lung nodule.

[0269] Commenced on NUC-1031 on 17 Oct. 2013 on 725 mg/m.sup.2 weekly, and completed 4 Cycles. Significant improvement in pain, with dramatic reduction in use of opioid analgesia. End of Cycle 4 CT Scan showed Progressive Disease.

Stable Disease to RECIST (4 months).

Patient 027 Ovarian Cancer: Stable Disease

[0270] Female (46 years)

[0271] Diagnosed with serous adenocarcinoma of both ovaries in December 2009. Following total hysterectomy, bilateral salpingo-oophorectomy and omentectomy she received 6 Cycles carboplatin+paclitaxel and achieved a Complete Response in May 2010. The patient relapsed in June 2011 and received carboplatin+paclitaxel 6 Cycles (ICON6 Study). In December 2012 the patient was given a further 3 Cycles of gemcitabine+carboplatin but had an allergic reaction to carboplatin which was switched to cisplatin. She completed 6 Cycles in total and achieved a partial response in April 2013. This was followed by 6 months of tamoxifen but in July 2013 a CT scan showed new mediastinal lymph node involvement and the CA125 levels increased. A CT scan in October 2013 showed an increase in the size of peritoneal deposits.

[0272] Commenced on NUC-1031 on 30 Oct. 2013 on 725 mg/m.sup.2 weekly. Developed elevated ALT (G3) following Cycle 1 Day 1, raised from 96 at baseline to 256 on day 7, a DLT for this cohort. ALT recovered to G2 a few days later to allow patient to receive Cycle 1 Day 8 at the reduced dose of 675 mg/m.sup.2. Completed Cycle 1 at reduced dose and went on to receive a further 3 Cycles. Patient achieved Stable Disease to RECIST with a reduction in tumour volume of 23%. CA125 has reduced from 188 at baseline to 99 at end of Cycle 6. Dose was further reduced for Cycle 5 to 625 mg/m.sup.2 due to mild neutropenia. Completed study at this dose with no further issues. Requested compassionate continuation and received 1 further Cycle.

Stable Disease to RECIST (8 months).

Patient 029 Breast Cancer: Stable Disease

[0273] Female (53 years)

[0274] Diagnosed with metastatic breast cancer (ER and PGR positive), with multiple bone and hepatic metastases in 2002. Received 6 Cycles of FEC, adjuvant radiotherapy and tamoxifen with goserelin. In 2010 new bone metastases detected and treated with Zoladex, letrozole and pamidronate. July 2011, switched to Zoladex and exemestane, which was augmented with Faslodex in November. On further progression in 2012 received capecitabine+Zometa, followed by paclitaxel for 3 Cycles only. Commenced treatment with rucaparib in May 2013. Progressive hepatic disease in July 2013 and received gemcitabine+carboplatin for 3 Cycles.

[0275] Commenced on NUC-1031 on 14 Nov. 2013 on 725 mg/m.sup.2 weekly. Completed 3 Cycles. Unfortunately suffered a fatal cardiac arrest while at home, not study related.

Stable Disease to RECIST (4 months).

Patient 030 Ovarian Cancer: Stable Disease

[0276] Female (62 years)

[0277] Diagnosed with serous adenocarcinoma of the ovary in 2012. Received adjuvant carboplatin+paclitaxel for 6 Cycles to July 2012, achieved complete response. Progressive disease in August 2013, commenced carboplatin+caelyx, progressed following 3 Cycles.

[0278] Commenced on NUC-1031 on 21 Nov. 2013 on 725 mg/m.sup.2 weekly. Completed 3 Cycles and tolerated study drug well. End of Cycle 2 CT scan showed Stable Disease to RECIST. Unstable dietary issues resulting in dehydration and malnutrition, which led to lengthy treatment delays. Withdrawn from study.

Stable Disease to RECIST (3 months).

Patient 031 Cholangiocarcinoma: Progressive Disease

[0279] Female (76 years)

[0280] Diagnosed with cholangiocarcinoma in July 2013. On the 27.sup.th July she underwent a modified Whipple's procedure. At the time of surgery she was noted to have multiple liver metastases. In August 2013 she commenced gemcitabine+oxaliplatin which was given every two weeks for 6 Cycles.

[0281] Commenced on NUC-1031 on 9 Dec. 2013 on 750 mg/m.sup.2 weekly and completed 2 Cycles. End of Cycle 2 CT scan showed Progressive Disease.

Withdrawn from study.

Patient 032 Oesophageal Cancer: Stable Disease

[0282] Male (56 years)

[0283] Diagnosed with squamous cell carcinoma of the oesophagus in June 2013. Received 3 Cycles of cisplatin+capecitabine from July to September 2013. Progressive disease with peritoneal and lung metastases. Oesophageal stent inserted in October 2013 to control symptoms of dysphagia.

[0284] Commenced on NUC-1031 on 16 Dec. 2013 on 750 mg/m.sup.2 weekly and completed 2 Cycles. End of Cycle 2 CT scan showed Stable Disease to RECIST. Patient was having difficulties with a lung/trachea fistulae. Withdrawn from study due to clinical progression.

Stable Disease to RECIST (2 months).

Patient 033 Cholangiocarcinoma: Stable Disease

[0285] Female (37 years)

[0286] Diagnosed with advanced cholangiocarcinoma in June 2013 with liver, peritoneal and para aortic lymph node metastases and small pulmonary nodules. In June she had a liver biopsy which showed a probable poorly differentiated cholangiocarcinoma, with some features to suggest a liver primary. In July 2013 she commenced chemotherapy with gemcitabine and cisplatin and received 6 Cycles omitting some of Cycle 5 due to an admission for neutropenic sepsis.

Unfortunately, although her interval scan showed a partial response her post treatment CT scan on the 28 Nov. 2013 showed progressive disease with a stable liver lesion but an increase in the size of her pulmonary metastases and some new peritoneal deposits. She also is known to have a lytic sternal lesion.

[0287] Commenced on NUC-1031 on 3 Jan. 2014 on 750 mg/m.sup.2 weekly and completed 4 Cycles. End of Cycle 2 CT scan showed Stable Disease to RECIST. End of Cycle 4 scan showed progressive disease and patient was withdrawn from the study.

Stable Disease to RECIST (3 months)

Patient 036 Renal Carcinoma: Stable Disease

[0288] Male (20 years)

[0289] Diagnosed with medullary cell renal carcinoma in December 2012. Received 5 Cycles of gemcitabine+paclitaxel+carboplatin from January until July 2013 resulting in Stable Disease during treatment. Patient had treatment delays due to thrombocytopenia and neutropenia which required intervention with G-CSF. Following relapse in July 2013 commenced gemcitabine+doxorubicin but progressed through 2 Cycles in September 2013.

[0290] Commenced on NUC-1031 28 Jan. 2014 on 825 mg/m.sup.2 weekly and completed 4 Cycles. Patient experienced fatigue and tiredness during Cycle 1. Lorazepam was discontinued and he became much more alert. He reported that he was tolerating NUC-1031 much better than his previous regimen. End of Cycle 4 CT scan showed sustained Stable Disease with a reduction in tumour volume of 7%. Following Cycle 5 Day 1 developed thrombocytopenia (G3) and dose was reduced to 750 mg/m.sup.2. Following Cycle 5 Day 8 developed fatigue, loss of appetite and did not present for any further treatment. Withdrawn from study due to clinical progression.

Stable Disease to RECIST (5 months).

Patient 037 Pancreatic Cancer: Partial Response

[0291] Female (70 years)

[0292] Diagnosed with pancreatic adenocarcinoma in March 2013. Whipple's procedure was planned for 26 Mar. 2013 but due to extensive adhesions the cancer was non-resectable, but biopsies were taken. Liver wedge resection confirmed metastatic disease. Histology showed moderately differentiated adenocarcinoma. Patient received 6 Cycles of gemcitabine from May to October 2013. CT scan November 2013 suggested partial response of pancreatic tumour, but with new metastases in the lateral left lobe of the liver.

[0293] Commenced on NUC-1031 4 Feb. 2014 on 1,000 mg/m.sup.2 weekly and received 1 Cycle at this dose. At this time the DSMC decided to reduce the dose in all patients in this cohort to 900 mg/m.sup.2 due to a DLT in one patient (patient 039). Patient received one further Cycle at the new dose. End of Cycle 2 CT scan showed Stable Disease to RECIST with an 18.4% reduction in tumour volume.

[0294] Pain in abdomen and back had significantly improved; patient was on oxycontin 80 mg bd and had now stopped all morphine. Also had a very significant drop in tumour markers: CA19.9 from 15,000 at baseline to 4,000 and CEA from 536 at baseline to 42. Fatigue had become a major issue following each cycle. CT scan on 29 Apr. 2014 showed a further reduction in tumour volume to 30% to achieve a Partial Response to RECIST. Patient had loss of appetite, severe fatigue and was withdrawn from the study.

Partial Response to RECIST (1 month; PFS 4 months).

Patient 038 Ovarian Cancer: Progressive Disease

[0295] Female (65 years)

[0296] Diagnosed with recurrent stage 3c grade 3 serous adenocarcinoma of the ovary in 2000. She underwent a total abdominal hysterectomy, with bilateral salpingo-oophorectomy and debulking surgery, leaving minimal residual disease, in November 2000. Received 6 Cycles of 3 weekly carboplatin+paclitaxel until March 2001. Following relapse in 2002 received 6 cycles of Carboplatin plus Etoposide to complete remission in March 2003. Further relapse in 2005 and had more debulking surgery, followed by carboplatin+gemcitabine×6 Cycles which finished in July 2006 with complete response. Additional debulking surgery, including splenectomy, was required following relapse in 2009. This was followed by 6 Cycles of carboplatin+caelyx and a complete response was achieved. A right pelvic recurrence near the right external iliac vessel, which was considered to be inoperable, was noted in 2010. The patient received carboplatin and paclitaxel for 6 Cycles, which she completed in April 2011, with a partial response. In October 2011 she showed evidence of progression, received topotecan for 6 Cycles till March 2012 and had stable disease. At this time she underwent insertion of a right ureteric stent for hydronephrosis. In June 2012, after further disease progression with new bilateral lung metastases, she was started on weekly carboplatin+paclitaxol+bevacizumab to March 2013 followed by maintenance bevacizumab+letrozole to September 2013. This was followed by 3 Cycles of cyclophosphamide+bevacizumab, but interval scan showed progressive disease and on 11 Nov. 2013 her treatment was discontinued.

Right ureteric stent changed January 2014.

[0297] Commenced on NUC-1031 on 4 Mar. 2014 on 900 mg/m.sup.2 weekly and completed 2 Cycles. Main toxicity was delayed onset fatigue, which set in on days 3 to 4. End of Cycle 2 scan showed progressive disease with a 25% increase in tumour volume. Withdrawn from the study.

Progressive Disease.

Patient 040 Cholangiocarcinoma: Stable Disease

[0298] Female (69 years)

[0299] Diagnosed in May 2013 with intrahepatic grade 2 cholangiocarcinoma, with 11 cm liver mass obstructing the common bile duct and causing jaundice. A biliary stent was inserted. Received 7 Cycles Gemcitabine+Cisplatin from August to December.

[0300] Commenced on NUC-1031 on 20 Feb. 2014 on 1,000 mg/m.sup.2 weekly and received 1 dose. Presented for Cycle 1 Day 8 on 27.sup.th February with fever, rigors and an elevated bilirubin. Was admitted, and source of infection (G3) was a stent blocked with tumour and a biliary tract cyst. Two new stents were working well. Cycle 1 was completed at 900 mg/m.sup.2 due to DLT in that cohort. Completed 3 Cycles. End of Cycle 2 CT scan on 23.sup.rd May showed Stable Disease to RECIST with slight reduction in tumour volume from 85 at base to 82.1. CA 19.9 dropped from 664 at baseline to 155 on 4.sup.th June. Was admitted with delirium in June 2014 and diagnosed with a urinary tract infection. Further investigation also revealed progressive disease in the liver. Withdrawn from study.

Stable Disease to RECIST (4 months).

Patient 041 Breast Cancer: Stable Disease

[0301] Female (54 years)

[0302] Diagnosed with metastatic invasive ductal breast cancer (ER and PR+ve) with bilateral axillary nodes, lung and liver metastases. Received FEC×3 Cycles, paclitaxel×9 Cycles, capecitabine×8 Cycles, euribulin×3 Cycles and gemcitabine+carboplatin×1 dose. Her last dose of chemotherapy was on the 19 Dec. 2013 and the last CT scan before enrolment showed progressive disease.

Commenced on NUC-1031 on 18 Mar. 2014 on 900 mg/m.sup.2 weekly and completed 3 Cycles. Had 2 treatment delays following Cycle 1 Day 8 and Day 15 due to neutropenia, which resolved spontaneously within one week. End of Cycle 2 CT scan showed Stable Disease to RECIST. CA 15.3 tumour marker was 726 at base 845 at C2 and was 824 on 19 May 2014. (This tumour marker has always been a reliable indicator of response in the past). Experiencing fatigue (G3) during Cycle 3 but had managed to reduce opioids significantly. NUC-1031 dose reduced to 825 mg/m.sup.2 for Cycle 4. End of Cycle 4 scan showed progressive disease with increase at target sites and new bone lesions. Withdrawn from study.
Stable Disease to RECIST (4 months)

Patient 042 Cholangiocarcinoma: Progressive Disease

[0303] Male (48 years)

[0304] Diagnosed with metastatic cholangiocarcinoma in January 2013. Partial hepatectomy in February 2013. Commenced on the BILCAP trial observation arm (comparing capecitabine with observation after surgery for biliary tract cancer). On progression commenced on gemcitabine and cisplatin×6 Cycles. On further progression in November 2013 he commenced capecitabine. However, this was stopped after two months as he developed angina. On further progression he was commenced on 5FU×6 weeks but had progressive disease with lung, liver and bone metastases.

[0305] Last treatment was in January 2014. Received palliative radiotherapy for pain in right shoulder bone metastasis on the 20 Jan. 2014.

[0306] Commenced on NUC-1031 on 18 Mar. 2014 on 900 mg/m.sup.2 weekly and completed 2 Cycles. Experienced delayed onset fatigue (G2) on days 3-5 following study drug. End of Cycle 2 CT scan showed a 9% reduction in tumour volume of primary target lesion but showed new pulmonary and bone lesions. Withdrawn from the study. Progressive Disease.

Patient 043 Ovarian Cancer: Stable Disease

[0307] Female (54 years)

[0308] Diagnosed with stage 4, Grade 3 papillary serous peritoneal cancer. A total abdominal hysterectomy, with bilateral salpingo-oophorectomy and omentectomy performed in September 2007. Received carboplatin+paclitaxel×4 Cycles followed by 2 Cycles of Carboplatin alone, due to neuropathy, and completed course in January 2008. In April 2011 underwent secondary debulking surgery for recurrent pelvic mass. Patient did not wish to have adjuvant chemotherapy or radiotherapy. Further recurrence of disease July 2012 and a stent inserted for hydronephrosis. Recurrent disease in August 2012 and commenced carboplatin+gemcitabine. CT scan in March 2013 revealed disease progression; patient completed 6×Cycles of Caelyx in October 2013. Progressive disease early 2014 with pleural effusion, which required very regular drainage.

[0309] Commenced on NUC-1031 on 20 Mar. 2014 on 900 mg/m.sup.2 weekly and completed 6 Cycles. Received PET scan on 7 Apr. 2014 which showed stable disease and SUV had gone down in some target tumours. CA125 had reduced from 1.099 at baseline to 783 at the beginning of Cycle 2. The volume of fluid from the pleural effusion also reducing (was draining 300 ml per week, now 150 ml per week). Developed delayed onset fatigue (G2) on days 4 and 5 and G1 at all other times. End of Cycle 6 CT scan showed Stable Disease to RECIST with an overall 10% reduction in tumour volume from baseline. CA125 fell from 1,099 at baseline to 910 on 15.sup.th July. Completed study and requested compassionate continuation. Dose reduced to 750 mg/m.sup.2 for Cycle 7 and received 1 further Cycle. Leg oedema developed to G3, no disease progression but new treatment options sought and withdrawn from study.

Stable Disease to RECIST (13 months).

Patient 044 Lung Cancer: Stable Disease

[0310] Female (64 years)

[0311] Diagnosed with adenocarcinoma of the lung (left lower lobe) February 2010 following unresolved cough for 7 months. Between January 2011-April 2012 patient received Gefitinib 250 m, but had progressive disease. Received Afatinib from April 2012 to November 2012 (but dose reduction due to skin toxicity) but again with progressive disease. From November 2012 to June 2013 patient given Erlotinib after worsening cough and progression of the primary lesion. In June 2013 developed abnormal vision and black shadows in left eye and found to have choroidal metastases for which she received radiotherapy to both eyes, with improvement of her vision. In June 2013—started pemetrexed+carboplatin for 6 Cycles followed by maintenance pemetrexed until 6 Feb. 2014 when progressive disease was diagnosed.

[0312] Commenced on NUC-1031 on 27 Mar. 2014 at 900 mg/m.sup.2 weekly and had completed 2 Cycles. Had a G3 lung infection on 19.sup.th April which responded well to antibiotics. Commenced Cycle 2 on a reduced dose, 825 mg/m.sup.2 and completed a further 2 Cycles. End of Cycle 2 CT scan showed Stable Disease to RECIST with a 10% reduction in tumour volume. Had 2 treatment delays for ascites drainage and two more for thrombocytopenia. End of Cycle 4 scan showed progressive disease in lung and new liver metastases. Withdrawn from study.

Stable Disease to RECIST (5 months).

Patient 046 Adrenal Carcinoma: Stable Disease

[0313] Male (36 years)

[0314] Diagnosed in August 2011 with a large 20×19×9 cm adrenocortical carcinoma. Ki 67 35-40% mitotic count 25/50hpf, Weiss score 6 with tumour extending to 0.3 mm of external margins but no renal involvement. Received adjuvant mitotane until January 2012 when it was stopped due to nausea and diarrhoea. Recommenced mitotane in June 2012. Relapsed in June 2013 with new liver metastases and commenced etoposide+carboplatin.

Staging CT scan on September 2013 showed differential response but overall stable disease, and he received a further 3 Cycles and remained stable on completion in November 2013. In January 2014 showed progressive disease in the liver.

[0315] Commenced on NUC-1031 on 16 Apr. 2014 on 1,000 mg/m.sup.2 weekly and completed 1 Cycle. During Cycle 1 experienced delayed onset fatigue, nausea and vomiting (all G3). Dose was reduced to 900 mg/m.sup.2 for Cycle 2 and received a further 5 Cycles on this dose to complete the study. End of Cycle 6 CT scan showed a 12.6% reduction in tumour volume from baseline. Requested compassionate continuation and completed 3 further Cycles. Developed fatigue (G3) and neutropenia (G2) following Cycle 8 D1, was dose reduced to 750 mg/m.sup.2 for Cycle 8 and received 2 further Cycles. Though improved to G1, fatigue continued, also developed nausea and vomiting and dose was further reduced to 625 mg/m2 for C11. Received 2 further doses. Withdrawn from study.

Stable Disease to RECIST (11 months).

Patient 048 Ovarian Cancer: Stable Disease

[0316] Female (63 years)

[0317] Diagnosed with stage 1a granulosa cell tumour of the ovary in 2000 and had total abdominal hysterectomy and bilateral salpingo-oophorectomy+omentectomy. On recurrence in February 2004 commenced 3 cycles of BEP (bleomycin+etoposide+cisplatin) to disease progression. Secondary debulking in July 2004.

[0318] In June 2006 underwent partial hepatectomy, splenectomy and excision of deposits from stomach and peritoneam. This was followed by radiofrequency ablation to liver deposits. Underwent laparotomy and resection of 4 further metastatic deposits in September 2008. In March 2009 commenced 3 weekly carboplatin+paclitaxel, with a mixed response. Changed to weekly carboplatin+low dose paclitaxel on May 12, 2009. Completed in October 2009 with PR and CA-125 negative. Further debulking surgery October 2011, with complications requiring prolonged stay in ITU. CT scan in April 2014 showed lesion in segment 8 of liver had increased in size, new small peritoneal metastases in the gastro-hepatic ligament and some new small volume lymphadenopathy in the small bowel mesentery and further small peritoneal deposits in the pelvis around the recto-sigmoid junction.

[0319] Commenced on NUC-1031 on 29 Apr. 2014 on 1,000 mg/m weekly and received 1 dose. Following Cycle 1 Day 1 developed; ALT, (G3, a DLT); AST and neutropaenia (G2); ALP (G1). Dose reduced to 900 mg/m.sup.2 for Cycle 1 Day 8. ALT returned to G3 following days 8 and 15. Dose for Cycle 2 reduced to 825 mg/m.sup.2. Results from PET scan at end of Cycle 1 showed stable disease and reduction in SUV at target sites. In January 2014 inhibin B was 430 and increased to 1,038 prior to study entry. July 2014 inhibin B had stabilized to 1,106, August 1148, September 1053. Dose reduced for Cycle 4 Day 15 to 750 mg/m.sup.2 due to neutropenia (G3) despite intervention with G-CSF. Completed study on this dose. End of Cycle 6 CT scan on 11.sup.th November confirmed Stable Disease to RECIST. Requested compassionate continuation. Due to diarrhoea following each dose, commenced Cycle 7 at the reduced dose of 625 mg/m.sup.2. Developed emboli close to Hickman line, and although this responded to clexane the patient was withdrawn from study.

Stable Disease to RECIST (8 months).

Patient 050 (202) Oesophageal Cancer: Progressive Disease

[0320] Female (41 years)

[0321] Diagnosed with Stage 4 squamous cell carcinoma of the oesophagus with liver metastases in November 2013. Received 6 Cycles of cisplatin+capecitabine from December 2013 until April 2014. Her post-treatment scan showed progressive disease, and new lung deposits.

[0322] Commenced on NUC-1031 on 21.sup.stMay 2014 on 900 mg/m.sup.2 weekly and received 3 Cycles. Following Cycle 1 Day 1 developed ALT and fatigue, both G3, and had dose reduction for Cycle 1 Day 8. End of Cycle 2 scan seemed to show Disease Progression, though uncertainty over some baseline lesions.

[0323] As patient was deriving clinical benefit with improvement in her dysphagia, it was decided to allow one more cycle. End of Cycle 3 scan confirmed Disease progression and patient was withdrawn from study.

Progressive Disease.

Patient 051 (203) Anal Cancer: Progressive Disease

[0324] Female (51 years)

[0325] Diagnosed with metastatic squamous cell carcinoma of the anus in October 2013. Progressed following 6 Cycles of cisplatin+5FU from October 2013 until March 2014.

[0326] Commenced on NUC-1031 on 3 Jun. 2014 on 900 mg/m.sup.2 weekly and has received 2 Cycles. Required blood transfusion during Cycle 2 but tolerated treatment well. End of Cycle 2 CT scan showed progressive disease.

Progressive Disease.

Patient 052 (204) Oesophageal Cancer: Stable Disease

[0327] Male (66 years)

[0328] Diagnosed with stage IV oesophageal cancer in December 2012. Received FOX from January 2013 until July 2013, with a Partial Response. Showed Progressive Disease in April 2014. Oesophageal stent inserted.

[0329] Commenced on NUC-1031 on 10 Jun. 2014 on 900 mg/m.sup.2 weekly and completed 1 Cycle. Due to fatigue dose was reduced to 825 mg/m.sup.2 for Cycle 2, with good effect. Completed 2 further Cycles at this dose. End of Cycle 2 CT scan showed Stable Disease to RECIST. Continues to have bone pain but scans revealed that this is not disease related. Dysphagia was becoming exacerbated. End of Cycle 4 CT scan on 10.sup.th November revealed Disease Progression.

Stable Disease to RECIST (5 months).

Patient 053 (205) Colon Cancer: Progressive Disease

[0330] Female (31 years)

[0331] Diagnosed with a T3 N1 MO adenocarcinoma of the colon in 2008. Resected and received 12 Cycles of FOLFOX, which was completed in 2009. On progression in 2011, received 13 cycles of FOLFIRI (6 of the cycles included Avastin). With further progression in 2012, received 12 Cycles of FOLFOX (6 of the Cycles included Avastin). Further Progressive Disease in January 2014, with metastases to the lungs and vertebrae. Received radiotherapy to the spine.

[0332] Commenced on NUC-1031 on 12 Jun. 2014 on 900 mg/m.sup.2 weekly and has completed 1 Cycle. Has developed a series of infections, and has required a de-functioning ileostomy. Following many treatment delays received Cycle 2 Day 15 and end of Cycle 2 CT scan showed Progressive Disease with new lesions in the lung and liver.

Progressive Disease.

Patient 055 (207) Ovarian Cancer: Stable Disease

[0333] Female (42 years)

[0334] Diagnosed in January 2002 with stage 2c grade 1 papillary serous adenocarcinoma of the ovary. Underwent, total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy with 6 Cycles of adjuvant carboplatin+paclitaxel, completing treatment in June 2002.

[0335] In January 2012 developed a new grade 3 stage 3c primary peritoneal cancer involving the recto-sigmoid junction. Underwent posterior exenteration, comprising resection of caecum, rectum and sigmoid plus omentectomy and peritoneal stripping. From March to August 2012 received 6 Cycles of adjuvant carboplatin+paclitaxel.

[0336] On disease recurrence in January 2013 received 6 Cycles of weekly paclitaxel until May 2013. Following further progression in October 2013 commenced 3 weekly paclitaxel+carboplatin+daily AKT inhibitor within the AKTRES study. In May 2014 CT showed new lesions and progressive disease.

[0337] Commenced on NUC-1031 on 2 Jul. 2014 on 900 mg/m.sup.2 weekly and received 1 Cycle. Dose was reduced to 825 mg/m.sup.2 for Cycle 2 due to fatigue and completed 4 further Cycles. Experienced nausea and vomiting post chemotherapy, dose reduced to 625 mg/m.sup.2 for Cycle 6 and completed one further cycle. End of Cycle 6 CT scan on 16 Dec. 2014 showed continued Stable Disease to RECIST with a reduction in tumour volume of 18% from baseline. Patients CA 125 was 36 at baseline and was 24 in January 2015. Completed study and requested compassionate continuation. Received 2 further Cycles under the Compassionate Access Programme with no further issues. Patient elected to come off study as she was traveling a great distance and requested the break.

Stable Disease to RECIST (10+ months).

Patient 057 (209) Ovarian Cancer: Stable Disease

[0338] Female (58 years)

[0339] Diagnosed with Stage 3c grade 3 serous ovarian cancer in October 2011. Received 3 Cycles of neo-adjuvant carboplatin+taxol, but developed taxol allergy on Cycle 3. Underwent posterior exenteration, ovarian debulking, anterior resection with a primary anastomosis, and omentectomy on 21 Dec. 2011. Completed 3 Cycles of carboplatin+docetaxel in March 2012. Relapsed in June 2013 and received 6 Cycles of carboplatin+caelyx until November 2013. In February 2014 had CT evidence of recurrent disease and received 3 Cycles of carboplatin+gemcitabine from March till June 2014.

[0340] Commenced on NUC-1031 on 9 Jul. 2014 on 900 mg/m.sup.2 weekly and received 2 doses. Presented for Cycle 1 Day 15 on 30.sup.th July with anaemia and ascites both G3.

Dose reduced to 825 for Cycle 2 and received 2 further Cycles. End of Cycle 4 CT scan showed continued Stable Disease to RECIST with a reduction in tumour volume of 10% from baseline.
Has a pleurx drain in and approximately 1,000 mls of very bloody fluid are withdrawn every other week. Further dose reduction to 750 mg/m.sup.2 from Cycle 4 Day 1 due to fatigue, received one further cycle. Abdominal fluid increasing. Withdrawn from study due to clinical progression.
Stable Disease to RECIST (5 months)

Patient 058 (210) Lung Cancer: Stable Disease

[0341] Male (54 years)

[0342] Diagnosed with metastatic non-small cell lung adenocarcinoma, with lymph node and bone metastases in January 2014.

[0343] Commenced 3 Cycles of cisplatin and pemetrexed with a response of Stable Disease. March 2014 commenced maintenance pemetrexed, received 4 Cycles until April 2014. In May 2014 showed progressive disease with bilateral pulmonary metastases and received 1 more dose of pemetrexed.

[0344] Commenced on NUC-1031 on 14 Jul. 2014 on 825 mg/m.sup.2 weekly and received 1 Cycle. Cycle 1 Day 15 was delayed one week due to G3 transaminitis (ALT), a DLT, and dose was reduced to 750 mg/m.sup.2. However some of the elevation in liver enzymes may be due to a congenital liver condition. Received 1 further Cycle at 750 mg/m.sup.2. End of Cycle 4 CT scan showed Progressive Disease with new lesions in the bones.

Stable Disease to RECIST (4 months)

Patient 059 (211) Cervical Cancer: Stable Disease

[0345] Female (52 years)

[0346] Diagnosed with stage IV squamous cell carcinoma of cervix in December 2012. Commenced on carboplatin+taxol chemotherapy, which was stopped due to toxicity, especially from the taxol, (rash and itching), in February 2013. Commenced 6 Cycles of cisplatin+topotecan from March 2013 until July 2013 and achieved Stable Disease. CT scan in October 2013 showed disease progression. She received 30Gy in 10 fractions pelvic radiotherapy, which was completed in November 2013. Commenced gemcitabine+carboplatin in December 2013 and received 3 Cycles. However, an interval CT scan in February 2014 showed disease progression.

[0347] Commenced on NUC-1031 on 24 Jul. 2014 on 825 mg/m.sup.2weekly and completed 1 Cycle. Cycle 1 Day 15 was delayed for 1 week due to thrombocytopenia (G3). Dose reduced to 750 mg/m.sup.2 for Cycle 2 and completed 2 further Cycles. End of Cycle 4 CT scan showed continuing Stable Disease to RECIST. Dose reduced to 625 mg/m.sup.2 for Cycle 4 due to fatigue (G3) experienced during Cycle 3 with good effect. Completed 2 further Cycles at this dose. Urinary stents made patient very uncomfortable and replaced in January 2015. During Cycle 6 patient reported to be very tired and elected to come off study.

Stable Disease to RECIST (7 months).

Patient 060 (212) Pancreatic Cancer: Progressive Disease

[0348] Male (83 years)

[0349] Diagnosed with metastatic pancreatic cancer (moderately differentiated adenocarcinoma), with multiple liver metastases, in January 2014. Elected to have palliative chemotherapy on the Maestro study (gemcitabine on day 1, 8 and 15 and hypoxia activated TH302) from January to June 2014 but had progressive disease.

[0350] Commenced on NUC-1031 on 5 Aug. 2014 on 825 mg/m.sup.2 weekly and completed 1 Cycle. Presented on 10.sup.th September with ALP, AST, ALT, all G3. Required new stent. Following treatment delays completed Cycle 2 on 1.sup.st October. CT scan showed Progressive Disease with new liver lesions.

Progressive Disease.

Patient 061 (213) Colorectal Cancer: Stable Disease

[0351] Female (53 years)

[0352] Diagnosed with colon cancer in 2012. Surgery, involving bilateral salpingo-oophorectomy, omentectomy and a loop ileostomy. Commenced 12 Cycles of FOLFOX from January to July 2013. Following disease recurrence in April 2014 she received 8 Cycles of FOLFIRI and cetuximab from April to July 2014. Had severe nausea and vomiting to all chemotherapy.

[0353] Commenced on NUC-1031 on 11 Aug. 2014 on 825 mg/m.sup.2 weekly and completed 4 Cycles. Had no nausea or vomiting during treatment. End of Cycle 2 CT scan showed Stable Disease to RECIST with a 2% reduction in tumour volume. End of Cycle 4 CT scan showed Progressive Disease with new lesions in the spleen and liver.

Stable Disease to RECIST (3 months).

Patient 063 (215) Ovarian Cancer: Stable Disease

[0354] Female (78 years)

[0355] In May 2011 was diagnosed with concurrent vulval melanoma (Clark's level 4) and a stage 3b ovarian cancer. Commenced 3 Cycles of carboplatin+paclitaxel from August to September 2011, followed by interval de-bulking surgery, comprising total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy. She then received a further 3 Cycles of carboplatin+paclitaxel, completing treatment in November 2011. On disease progression, commenced 6 Cycles of gemcitabine+carboplatin+Avastin from September 2013 to February 2014. Then received 2 Cycles of caelix from April to June 2014.

[0356] Commenced on NUC-1031 on 27 Aug. 2014 on 825 mg/m.sup.2 weekly and received 1 Cycle. Dose reduced to 750 mg/m.sup.2 for Cycle 2 Day 15 due to anaemia and neutropenia and received 2 further Cycles. End of Cycle 2 CT scan showed Stable Disease to RECIST. Dose reduced to 625 mg/m.sup.2 for Cycle 4 Day 1 due to fatigue (G3), experienced on Cycle 3. Developed persistent shortness of breath. Removed from study.

Stable Disease to RECIST (3 months).

Patient 064 (216) Trophoblastic Cancer: Progressive Disease

[0357] Female (38 years)

[0358] In June 2011 was diagnosed with recurrent stage 3 mixed placental site and epithelioid trophoblastic tumour (PSTT/ETT). Following radical hysterectomy and lymph node sampling received adjuvant chemotherapy with paclitaxel+cisplatin ultimately with paclitaxel+etoposide from June to October 2011 followed by surgery for lymph leakage in November 2011 and a bilateral ureteric implantation February 2012.

[0359] In February 2013 underwent a left oophorectomy and resection of bladder serosa for recurrent disease and was given adjuvant chemotherapy of high dose etoposide from March to July 2013, followed by autologous stem cell transplant. January 2014 underwent posterior exenteration, comprising resection of the upper vagina, rectum and bladder, removal of the left ovary, anterior vagina, a mesenteric nodule and right ureter. Received 5 Cycles of pemetrexed+carboplatin from February to May 2014. This was switched to gemcitabine+carboplatin, due to rising HCG levels. Received 2 Cycles but interval CT scan showed left lower lobe lung lesion which was considered inoperable.

[0360] Commenced on NUC-1031 on 3 Sep. 2014 on 825 mg/m.sup.2 weekly and has received 2 Cycles. End of Cycle 2 CT scan showed Progressive Disease, growth in existing lesions in lungs and peritoneum.

Progressive Disease.

Patient 066 (218) Colorectal Cancer: Stable Disease

[0361] Male (65 years)

[0362] In May 2011 was first diagnosed with pT4b pN0 moderately differentiated adenocarcinoma of the sigmoid colon. Underwent an anterior resection in November 2011 and commenced FOLFOX chemotherapy in January 2012. Developed peripheral neuropathy following 3 Cycles and was switched to 5FU monotherapy. Also troubled with delays due to diarrhoea and malaise. Following 3 months on 5FU showed a stable marker response but a mixed response on CT scan in July 2012. Remained stable off treatment until May 2013 showed progressing on his CT scan with the tumour markers levels doubling. Re-commenced 5FU+Avastin, which was completed in October 2013. Treatment was complicated with numerous hospital admissions with chest infections and chest pain. Received 8 Cycles of cetuximab from March to July 2014. CT scan showed disease progression and switched to 5FU plus Avastin. In June 2014 underwent a laparotomy and adhesiolysis because of adhesions from metastatic deposits within his peritoneum. Received a further cycle of Avastin but, with a rising CEA, was discontinued. Has many co morbidities, COPD, ischemic heart disease, and congestive cardiac failure.

[0363] Commenced on NUC-1031 on 16 Sep. 2014 on 825 mg/m.sup.2 weekly and received 2 Cycles. Dose reduction to 750 mg/m.sup.2 for Cycle 3 due to fatigue and received 1 further Cycle. End of Cycle 2 CT scan showed Stable Disease to RECIST.

Had two recent admissions for complications from a hernia, which resulted in treatment delays. Unscheduled CT scan on 30.sup.th December showed continued Stable Disease with reduction in tumour volume of 16% from baseline. Dose further reduced to 625 mg/m.sup.2 for Cycle 4 due to fatigue. Has received 1 further Cycle at this dose with no further issues. Admitted during Cycle 5 with acute back pain, old fracture noted (not study related). Continues under surgical evaluation. Withdrawn from study due to treatment delays.
Stable Disease to RECIST (8+ months).

Patient 067 (219) Osteosarcoma: Stable Disease

[0364] Male (38 years)

[0365] In May 2011 was diagnosed 24 Feb. 2012 with osteosarcoma of proximal right tibia. Received 6 Cycles of cisplatin+doxorubicin+methotrexate from February to November 2012. Had a proximal tibial replacement on November 2012 and received post chemotherapy mifamurtide for 6 months. CT scan in August 2014 showed metastatic recurrence with new intrapulmonary and pericardial lesion, inferior to IVC and adjacent to right atrium.

[0366] Commenced on NUC-1031 on 30 Sep. 2014 on 825 mg/m.sup.2 weekly and has received 5 Cycles. End of Cycle 4 CT scan showed Stable Disease to RECIST. Tends to develop neutropenia G2 towards the end of each Cycle but counts bounce back quickly. Completed study on 3 Mar. 2015. Tolerated study drug well. EOS CT scan showed Stable Disease to RECIST with an increase in 1% from baseline. Scan also showed significant calcification to tumour. Patient requested compassionate continuation of study drug and will completed C7 on 2 Apr. 2015 at the reduced dose of 750 mg/m2. Assessed by the thoracic surgeon who will operate on the left lung to remove the target lesion on the lower lobe on 26 Apr. 2015. Thoracic surgeons removed the calcified target lesion in the lower lobe on 26 Apr. 2015. The lesion was removed completely with a clear margin of normal surrounding tissue. The patient has made a good recovery from the operation.

Stable Disease to RECIST (7+ months).

Patient 068 (220) Lung Cancer

[0367] Male (60 years)

[0368] In May 2011 was diagnosed with T3 N3 M1b non-small cell carcinoma of the right lung (adenocarcinoma), EGFR wild type, in February 2013. Received 10 Cycles of pemetrexed and cisplatin from February to December 2013, followed by thoracic palliative radiotherapy. From January to May 2014 enrolled in the POPLAR study on the docetaxel arm.

[0369] Commenced on NUC-1031 on 3 Oct. 2014 on 825 mg/m.sup.2 weekly and received 2 Cycles. End of Cycle 2 CT scan showed Progressive Disease. Removed from study.

Progressive Disease.

Patient 069 (221) Colorectal Cancer

[0370] Female (45 years)

[0371] In May 2011 was diagnosed with colorectal cancer. In August 2011 received neo-adjuvant capecitabine with radiotherapy and then primary debulking surgery in December 2011. Received adjuvant FOLFOX from January to July 2012. In April 2013 developed a solitary lung recurrence, which was resected. July 2013, a right parieto-occipital recurrence was found and removed, along with some dermal and subcutaneous cancer deposits. Commenced on cetuximab with FOLFIRI from September 2013 and remained on maintenance cetuximab until September 2014. Gamma-knife treatment in September 2014 for brain metastasis. Is asymptomatic for neurological symptoms.

[0372] Commenced on NUC-1031 on 9 Oct. 2014 on 825 mg/m.sup.2 weekly and received 3 Cycles. PET scan on 30/10 showed Partial Response. During pre C2 examination cutaneous and sub cutaneous metastases were greatly reduced or almost vanished and no new ones have appeared. End of C2 CT scan showed Stable Disease to RECIST with an 11% reduction in tumour volume from baseline. Developed neutropenia (G4) and leukopenia (G3) during Cycle 3 and dose reduced to 750 mg/m.sup.2 for Cycle 4. End of C4 CT scan showed Stable Disease to RECIST with 26% reduction in tumour volume from baseline. Following Cycle 4 D1 developed neutropenia and leukopenia, G3 and was dose reduced to 675 mg/m.sup.2 for Cycle 4 D8. Dose was reduced to 625 mg/m.sup.2 for C5 D8 due to neutropenia and leukopenia, G2. Experiencing visual disturbances, CT scan showed lesion in brain had increased. This has been removed with cyberknife. She will recommence on study drug, C7 D1 on 29 Apr. 2015 at the reduced dose of 500 mg/m.sup.2.

Stable Disease to RECIST (7+ months).